证券代码：002688 证券简称：金河生物 公告编号：2026-001 金河生物科技股份有限公司 关于变更保荐机构后重新签订募集资金监管协议的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日披 露了《关于变更持续督导保荐机构及保荐代表人的公告》。因公司聘请平安证券 股份有限公司（以下简称"平安证券"）担任公司 2025 年度以简易程序向特定 对象发行股票的保荐机构，原保荐机构东方证券股份有限公司（以下简称"东方 证券"）对公司 2021 年度非公开发行股票并上市尚未完成的持续督导工作由平 安证券承接。鉴于公司保荐机构已变更，为规范募集资金管理和使用，保护中小 投资者的权益，根据《上市公司募集资金监管规则》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关法律、法规和规范性文 件及公司《募集资金管理办法》的相关规定，近日，公司与中国民生银行股份有 限公司呼和浩特分行、平安证券共同签订《募集资金三方监管协议》；公司及控 股子公司金河佑本生 ...

Core Viewpoint - The animal health sector experienced a 0.99% increase on January 8, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4082.98, down 0.07%, and the Shenzhen Component Index closed at 13959.48, down 0.51% [1]. - The animal health sector stocks showed varied performance, with BioShares leading the gains at 3.10% [1]. Group 2: Stock Performance - Key stocks in the animal health sector included: - BioShares (600201) closed at 16.61 with a 3.10% increase and a trading volume of 517,400 shares, totaling 853 million yuan [1]. - Huisheng Biological (300871) closed at 22.46, up 2.23%, with a trading volume of 86,000 shares, totaling 193 million yuan [1]. - Dayu Biological (920970) closed at 8.02, up 2.17%, with a trading volume of 19,900 shares, totaling 15.81 million yuan [1]. - Other notable stocks included PlaiKe (603566) and Shunlian Biological (688098), with increases of 1.90% and 1.71% respectively [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 10.1262 million yuan from institutional investors, while retail investors contributed a net inflow of 37.4241 million yuan [2]. - Notably, the main funds showed a net outflow of 47.5503 million yuan from speculative funds [2]. Group 4: Detailed Capital Flow by Stock - BioShares (600201) had a net inflow of 40.3094 million yuan from main funds, while it experienced a net outflow of 8.4352 million yuan from speculative funds [3]. - Gold River Biological (002688) saw a net inflow of 13.2219 million yuan from main funds, with a net outflow of 3.8181 million yuan from speculative funds [3]. - ST Green Health (002868) had a net inflow of 9.7760 million yuan from main funds, but a significant net outflow of 20.7609 million yuan from speculative funds [3].

Group 1 - The company has successfully established a production capacity of 3,000 tons of astaxanthin per year [1] - The related product, red yeast rice as a feed additive, has received the necessary product approval number and is currently in the market promotion phase [1] - The company is expected to provide further details on the operational situation in future announcements [1]

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

证券日报网讯 12月30日，金河生物（002688）发布公告称，公司拟为全资子公司金河环保向建设银行 呼和浩特分行申请的10，000万元固定资产贷款提供连带责任保证担保，用于污水处理厂扩容及水资源 再生利用提标扩建工程。截至公告披露日，公司及子公司累计对外担保余额为46，305.34万元，占公司 2024年经审计归属于母公司所有者净资产的20.61%，不存在逾期担保。 ...

Group 1 - The company announced that it will provide a guarantee for its wholly-owned subsidiary, Inner Mongolia Jinhai Environmental Technology Co., Ltd., to secure a loan of up to 100 million RMB from China Construction Bank for a wastewater treatment plant expansion project [1] - The loan is intended for a five-year term with an interest rate based on the current LPR rate, specifically for the project aimed at enhancing wastewater treatment capacity and water resource recycling [1] - As of the announcement date, the total external guarantee balance for the company and its subsidiaries is approximately 463 million RMB, which includes the new guarantee and represents 20.61% of the audited net assets attributable to the parent company for 2024 [1] Group 2 - The new guarantee amount of 100 million RMB will account for 4.45% of the audited net assets attributable to the parent company for 2024 [1] - The guarantee requires approval from the company's shareholders through a special resolution and does not involve related party transactions or require approval from relevant authorities [1]

Group 1 - The company Jinhe Biological announced the approval of several proposals during the 35th meeting of its sixth board of directors, including the repurchase and cancellation of certain restricted stocks [2] - The company plans to change its registered capital and amend certain clauses as part of its strategic initiatives [2] - A temporary shareholders' meeting is scheduled for January 16, 2026, to discuss these matters [2]

格隆汇12月30日丨金河生物(002688.SZ)公布，第六届董事会第三十五次会议，以9票同意，0票反对，0 票弃权审议通过了《关于对外投资设立全资子公司的议案》，同意公司以自有或自筹资金投资5,000万 元于内蒙古金河东汇生物科技有限公司。（最终以市场监督管理局核定名称为准）。 ...

Core Viewpoint - On December 30, Jinhe Biology announced the approval of an investment to establish a wholly-owned subsidiary, indicating a strategic move to expand its business operations [1] Group 1: Company Actions - The company held its 35th meeting of the sixth board of directors to discuss and approve the investment proposal [1] - Jinhe Biology plans to invest 50 million yuan in Inner Mongolia Jinhe Donghui Biotechnology Co., Ltd. using its own or raised funds [1]